Serum proteomics of glioma: Methods and applications

Expert Review of Molecular Diagnostics

Volumn 9, Issue 7, 2009, Pages 695-707

  Somasundaram, Kumaravel ^a   Nijaguna, Mamatha B ^a   Kumar, Durairaj Mohan ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

2D DIGE; 2DE; Anaplastic astrocytoma; Antibody array; Diffuse astrocytoma; ELISA; ESI; Glioblastoma; Glioma; LC MS MS; MALDI TOF; Protein array; SELDI TOF; Serum biomarker; Serum proteomics

Indexed keywords

ALPHA 2 HEREMANS SCHMID GLYCOPROTEIN; APRIL PROTEIN; BIOLOGICAL MARKER; CALDESMON; CATHEPSIN D; CHITINASE 3 LIKE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FETUIN A; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN E; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; NERVE CELL ADHESION MOLECULE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRE B CELL COLONY ENHANCING FACTOR 1; SOMATOMEDIN BINDING PROTEIN 2; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIBODY MICROARRAY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; DEVICE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE IDENTIFICATION; GENETIC HETEROGENEITY; GLIOBLASTOMA; GLIOMA; HUMAN; LIQUID CHROMATOGRAPHY; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; MONITORING; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT RESPONSE; TWO DIMENSIONAL ELECTROPHORESIS; VALIDATION PROCESS;

BRAIN NEOPLASMS; GLIOMA; HUMANS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 70350049244     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.52     Document Type: Review

References (46)

1. Kleihues P, Cavanee WK. World Health Organization: Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Barnes L, Eveson JW, Sidransky D (Eds). IARC Press, Lyon, France (2000).
2. Berger M, Wilson C. (Eds). The Gliomas. WB Saunders, PA, USA (1999).
3. Anderson NL, Anderson NG. The human plasma proteome history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867 (2002). •• Excellent review on serum proteomics providing information of complex nature of serum, different proteomics methods for serum proteomics and problems associated with translation of serum biomarkers into clinical usage.
4. Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 19(11), 1853-1861 (1998).
5. Blackstock WP, Weir MP. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 17(3), 121-127 (1999).
6. Steel LF, Habb BB, Hanash SM. Methods of comparative proteomic profiling for disease diagnostics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815(1-2), 275-284 (2005).
7. Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 26(3), 231-243 (1975).
8. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 250(10), 4007-4021 (1975).
9. Anderson L, Anderson NG. High resolution two-dimensional electrophoresis of human plasma proteins. Proc. Natl Acad. Sci. USA 74(12), 5421-5425 (1977).
10. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18(11), 2071-2077 (1997). • First report of differential gel electrophoresis. (Pubitemid 27501267)
11. Nagele E, Vollmer M, Horth P, Vad C. 2D-LC/MS techniques for the identification of proteins in highly complex mixtures. Expert Rev. Proteomics 1(1), 37-46 (2004). (Pubitemid 43826427)
12. Washburn MP, Wolters D, Yates JR III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19(3), 242-247 (2001). (Pubitemid 32220565)
13. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17(10), 994-999 (1999). (Pubitemid 29474856)
14. Patterson SD, Aebersold R. Mass spectrometric approaches for the identification of gel-separated proteins. Electrophoresis 16(10), 1791 - 1814 (1995). •• Provides extensive information on mass spectrometry methods, practical aspects, limitations, analysis in identification of gel-separated proteins.
15. Chen G, Pramanik BN. Application of LC/MS to proteomics studies: current status and future prospects. Drug Discov. Today 14(9-10), 465-471 (2009). • Describes various applications of liquid chromatography/mass spectrometry in proteomics.
16. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-575 (2002).
17. Powell K. Proteomics delivers on promise of cancer biomarkers. Nat. Med. 9, 980 (2003).
18. Diamandis EP. Point: proteomics patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 48(8), 1272-1275 (2003). • Technical limitations and controversial scientific issues about SELDI-TOF are discussed.
19. Haab BB. Antibody arrays in cancer research. Mol. Cell. Proteomics 4, 377-383 (2005). • Detailed picture of various types of antibody microarray methods and their application to cancer research.
20. Angenendt P, Kreutzberger J, Glokler J, Hoheisal JD. Generation of high density protein microarrays by cell-free in situ expression of unpurified PCR products. Mol. Cell. Proteomics 5(9), 1658-1666 (2006). (Pubitemid 44480393)
21. Kim BK, Lee JW, Park PJ et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res. 11(2), 22 (2009).
22. Stupp R, Reni M, Gatta G, Mazza E, Vecht C. Anaplastic astrocytoma in adults. Crit. Rev. Oncol. Hematol. 63(1), 72-80 (2007).
23. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11(2), 152-164 (2006).
24. Petrik V, Saadoun S, Loosemore A et al. Serum α2-hs glycoprotein predicts survival in patients with glioblastoma. Clin. Chem. 54(4), 713-722 (2008). • Glioblastoma multiforme serum biomarker was identified by a SELDI-TOF-MS/MS approach. (Pubitemid 351573704)
25. Zhang H, Wu G, Tu H et al. Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology. J. Neurooncol. 84(3), 315-332 (2007).
26. Azok J, Guccione S, Lim M et al. The use of magnetic resonance imaging to guide the analysis of serum proteomic patterns in glioblastoma multiforme. Proc. Intl. Soc. Mag. Reson. Med. 11, 220 (2004).
27. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 62(15), 4364-4368 (2002).
28. Reddy PS, Umesh S, Thota B et al. PBEF1/NAmPRTase/Visfatin a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol. Ther. 7(5), 663-668 (2008). (Pubitemid 351847000)
29. Hzecka A, Hzecki M. APRIL is increased in serum of patients with brain glioblastoma multiforme. Eur. Cytokine Netw. 17(4), 276-280 (2006).
30. Jung CS, Foerch C, Schänzer A et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130(12), 3336-3341 (2007). (Pubitemid 350209077)
31. Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol. Ther. 2(3), 242-247 (2003).
32. Hormigo A, Gu B, Karimi S et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer Res. 12(19), 5698-5704 (2006). (Pubitemid 44629598)
33. Iwadate Y, Hayama M, Adachi A et al. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res. 28(1B), 415-418 (2008). (Pubitemid 351362846)
34. Lin Y, Jiang T, Zhou K et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro. Oncol. DOI:10.1215/ 15228517-2008-114 (2009) (Epub ahead of print).
35. Quaranta M, Divella R, Daniele A et al. Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori 93(3), 275-280 (2007). (Pubitemid 47080014)
36. Fukuda ME, Iwadate Y, Machida T et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res. 65(12), 5190-5194 (2005). (Pubitemid 40827328)
37. Nano R, Capelli E, Argentina F, Facoetti A, Gerzeli G. Evaluation of serum levels of cytokines and intercellular adhesion molecule-1 (ICAM-1) in astrocytic tumours. Cell. Mol. Biol. 49(4), 525-528 (2003).
38. Ammirati M, Rao S, Granger G et al. Detection of TNF inhibitors (soluble receptors) in the sera and tumor cyst fluid of patients with malignant astrocytomas of the brain. Front. Biosci. 6, B17-B24 (2001).
39. Zheng PP, Hop WC, Sillevis Smitt PA et al. Low-molecularweight caldesmon as a potential serum marker for glioma. Clin. Cancer Res. 11(12), 4388-4392 (2005).
40. Wrensch M, Wiencke JK, Wiemels J et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res. 66(8), 4531-4541 (2006).
41. Guccione S, Yang Y, Chia Y et al. Identification of serum markers of glioblastoma multiforme patients using image-guided genomic and proteomic analysis. J. Clin. Oncol. 24(18 Suppl.), 20008 (2006).
42. Todaro L, Christiansen S, Varela et al. Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J. Neurooncol. 83(2), 135-144 (2007). (Pubitemid 46784986)
43. Mascot www.matrixscience.com
44. PepIdent www.unb.br/cbsp/paginiciais/pepident.htm
45. ProFound www.unb.br/cbsp/paginiciais/profound.htm
46. Genome fingerprint scanning http://gfs.unc.edu/cgi-bin/WebObjects/GFSWeb